11/20
06:20 pm
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $13.00 price target on the stock.
11/14
08:15 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Low
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
11/13
04:05 pm
imrx
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/15
09:05 am
imrx
Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]
Medium
Report
Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]
10/15
08:00 am
imrx
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
High
Report
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
10/14
09:44 am
imrx
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation [Yahoo! Finance]
9/16
11:29 am
imrx
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study [Yahoo! Finance]
High
Report
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study [Yahoo! Finance]
9/13
08:23 am
imrx
Why Is Nanocap Immuneering Stock Trading Higher On Friday? [Yahoo! Finance]
Low
Report
Why Is Nanocap Immuneering Stock Trading Higher On Friday? [Yahoo! Finance]
9/13
08:02 am
imrx
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
Medium
Report
Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.
9/13
12:25 am
imrx
Immuneering stock rockets 45% on pancreatic therapy data [Seeking Alpha]
Medium
Report
Immuneering stock rockets 45% on pancreatic therapy data [Seeking Alpha]
9/12
04:05 pm
imrx
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
High
Report
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
8/29
08:00 am
imrx
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Medium
Report
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
8/28
07:49 am
imrx
Favourable Signals For Immuneering: Numerous Insiders Acquired Stock [Yahoo! Finance]
Low
Report
Favourable Signals For Immuneering: Numerous Insiders Acquired Stock [Yahoo! Finance]